文献速递角膜与眼表疾病眼底病与葡萄膜炎

再生与癌症:干细胞硬币的两面——2025年Mildred Weisenfeld奖演讲

Regeneration and Cancer-The Two Sides of a "Stem Cell" Coin: The 2025 Mildred Weisenfeld Award Lecture.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该演讲综述了干细胞在眼表面再生与视网膜母细胞瘤癌症干细胞两方面的研究。培养的角膜缘上皮细胞移植重建严重角膜缘干细胞缺乏症眼表成功率为60%至70%;并分离鉴定了视网膜母细胞瘤癌症干细胞,探索小细胞外囊泡作为诊断预后标志物及纳米制剂逆转化疗耐药。

要点

  • 培养角膜缘上皮细胞移植重建严重角膜缘干细胞缺乏症眼表成功率达60%至70%。
  • 角膜缘和结膜细胞可在单膜环屏障上共培养,有效重建严重眼病患者的结膜和穹窿。
  • 视网膜母细胞瘤癌症干细胞研究聚焦逆转化疗耐药,小细胞外囊泡有诊断预后潜力。

核心结论

  • 培养角膜缘上皮细胞移植可有效重建严重角膜缘干细胞缺乏症的眼表,成功率为60%至70%。
  • 角膜缘和结膜细胞共培养于单膜环屏障可有效重建严重眼病患者的结膜和穹窿。
  • 视网膜母细胞瘤癌症干细胞研究显示小细胞外囊泡可能作为诊断和预后标志物。
  • 纳米制剂药物和载药小细胞外囊泡靶向递送在降低视网膜母细胞瘤化疗耐药方面显示前景。

研究设计与样本

  • 该演讲为2025年Mildred Weisenfeld奖演讲,综述了干细胞在眼表面再生和视网膜母细胞瘤癌症干细胞两方面的研究工作。
  • 再生部分涉及培养角膜缘上皮细胞移植、角膜缘与结膜细胞共培养及人泪腺组织培养。
  • 癌症干细胞部分涉及视网膜母细胞瘤原发肿瘤和Y79细胞系的分离与鉴定。

主要发现

  • 培养角膜缘上皮细胞移植重建严重角膜缘干细胞缺乏症眼表成功率为60%至70%。
  • 移植细胞存活、形成网络、整合、贡献功能且对患者无害。
  • 角膜缘和结膜细胞共培养于单膜环屏障可有效重建严重眼病患者的结膜和穹窿。
  • 鉴定出具有间充质干细胞特征的角膜缘来源基质细胞亚群。
  • 人泪腺组织培养显示存在上皮干细胞和具有分泌潜能的间充质干细胞。

关键数值与推荐

  • 培养角膜缘上皮细胞移植重建严重角膜缘干细胞缺乏症眼表成功率为60%至70%。

临床怎么用

  • 培养角膜缘上皮细胞移植可用于重建严重角膜缘干细胞缺乏症的眼表。
  • 角膜缘和结膜细胞共培养于单膜环屏障可用于重建严重眼病患者的结膜和穹窿。
  • 小细胞外囊泡可能作为视网膜母细胞瘤的诊断和预后标志物。
  • 纳米制剂药物和载药小细胞外囊泡靶向递送可能有助于降低视网膜母细胞瘤化疗耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stem cells endowed with properties of self-renewal and differentiation have opened new avenues for restoration and regeneration of damaged tissues. The same adult stem cells, when they undergo irreversible mutations, transform into cancer cells and generate a tumor. In this lecture, I present our work on these two aspects of stem cells: one focuses on regeneration of the ocular surface, whereas the other targets cancer stem cells (CSCs) in retinoblastoma (Rb). In regeneration, I present our experience of transplantation of the cultured limbal epithelial cells to restore the ocular surface in severe limbal stem cell deficiency, with 60% to 70% success. The technique proved that transplanted cells survive, network, integrate, contribute to function, and cause no harm to the patient. We also developed a technique wherein both limbal and conjunctival cells could be cultured on a single membrane utilized ring barrier. This approach was effective in reconstructing the conjunctiva and fornices in patients with severe ocular disease. Furthermore, our work led identification of a subpopulation of limbal-derived stromal cells with features of mesenchymal stem cells. We also saw success with culturing human lacrimal gland tissues marked by the presence of epithelial stem cells and mesenchymal stem cells with secretory potential. These cultures we believe could pave the way of lacrimal gland regeneration through cell therapy. We then flip to the "dark side" of stem cells: the isolation and characterization of CSCs in Rb. We worked on both primary tumors as well as Rb y79 cell lines, with a special focus on reversing their chemoresistant properties. Our work demonstrated the possible role of small extracellular vesicles in Rb as a diagnostic and prognostic marker. The reduction of chemoresistance using nano-formulated drugs and targeted delivery of drug-loaded small extracellular vesicles derived from the tumor cells shows promise.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Vemuganti GK. Regeneration and Cancer-The Two Sides of a "Stem Cell" Coin: The 2025 Mildred Weisenfeld Award Lecture. Invest Ophthalmol Vis Sci. 2026. PMID: 42836720. doi:10.1167/iovs.67.12.11

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。